Norwegian study finds possible treatment targets in over a quarter of patients with brain tumours
Published
A Norwegian research study has attracted attention at the ESMO Congress, a major European conference on cancer research. The researchers presented new results from the IMPRESS study, and they were the only researchers from Norway with a presentation at this conference.
In the study, the researchers examined 349 Norwegian patients with tumours in the central nervous system. The central nervous system consists of the brain and the spinal cord. The researchers performed molecular profiling, which means that they analysed the genetic and molecular content of the tumours. With this method, one can find special characteristics in the cancer cells.
The results show that in 28 per cent of the patients, the researchers found potential targets for treatment. A treatment target is a particular feature of the tumour that a drug can aim at. This does not mean that all these patients will automatically receive a new treatment, but it may provide a basis for more personalised treatment in the future.
For patients with tumours in the brain and spinal cord, it is important that there are new treatment options, because many of these diseases are difficult to treat. The IMPRESS study is ongoing, and the researchers will likely present more results in the future.
Sources: HealthTalk
More Norway news
- Cybersecurity has become a leadership responsibility
- Former soldier has built challenger to OBOS
- More Customers Don't Necessarily Mean Better Profitability
- New Norway chief at Advania
- Professor Moumita Sen researches religion, politics and power
- Conference in Oslo to examine how Norwegian life sciences can reach their potential
- From Emissions to Resource: Can CO₂ Be Used in New Industry?
- Norway heard in the EU's new Arctic strategy